http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. Vemurafenib has been approved since February 2012 for the treatment of certain groups of adults with advanced melanoma. The drug offers major advantages in terms of survival, but also causes major side effects. Overall, there is an indication of a considerable added benefit. This is the conclusion of a dossier assessment by the IQWiG, Cologne, which was published in June 2012 and for which an English-language extract is now available. http://medicalxpress.com/news/2013-01-indication-considerable-added-benefit-vemurafenib.html Cancer Tue, 08 Jan 2013 10:38:49 EST news276863922 (Medical Xpress)—Results of a University of Arizona Cancer Center's scientist-led clinical trial show that a drug already approved for breast and lung cancer improved progression-free survival in patients with metastatic melanoma. http://medicalxpress.com/news/2012-11-cancer-drug-survival-patients-metastatic.html Cancer Wed, 14 Nov 2012 08:20:40 EST news272103570 (HealthDay)—Despite more extensive disease and more adverse prognostic factors, HIV-positive patients with Hodgkin's lymphoma (HL) do not have worse outcomes when treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), according to research published online Oct. 8 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2012-10-hiv-status-doesnt-hodgkin-lymphoma.html Cancer Thu, 11 Oct 2012 19:00:01 EST news269194460 (HealthDay) -- New research suggests that a new drug does a better job of combating advanced skin cancer in melanoma patients than chemotherapy. http://medicalxpress.com/news/2012-06-melanoma-drug-survival.html Cancer Mon, 25 Jun 2012 14:38:24 EST news259853887 (HealthDay) -- For patients with metastatic melanoma with activating mutations in serine-threonine protein kinase B-RAF (BRAF), treatment with the oral selective MEK inhibitor trametinib is associated with improved progression-free and overall survival, compared with chemotherapy, according to a study published online June 4 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago. http://medicalxpress.com/news/2012-06-asco-trametinib-survival-metastatic-melanoma.html Cancer Tue, 05 Jun 2012 04:10:01 EST news258086357